NCT00462995View on ClinicalTrials.gov

Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT)

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

January 31, 2012

Study Completion Date

February 29, 2012

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Erlotinib

150mg once a day for 28 days

DRUG

Erlotinib

28 days of Erlotinib before surgery in patients with stage I-IIb NSCLC

Trial Locations (2)

M5G 2C4

Toronto General Hospital, Toronto

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

University Health Network, Toronto

OTHER

NCT00462995 - Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT) | Biotech Hunter | Biotech Hunter